BackTaiwan Bio Therapeutics , Ltd Overview

Taiwan Bio Therapeutics , Ltd Current Assets

Latest current assets for 6892.TWO: $470M.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$466.07M
↓ 25.01% YoYΔ $-155.43M vs prior year quarter

Peer trimmed avg / median

Loading

Taiwan Bio Therapeutics , Ltd Current Assets History

Loading

Taiwan Bio Therapeutics , Ltd vs. peers: Current Assets Comparison

Loading

Taiwan Bio Therapeutics , Ltd Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Taiwan Bio Therapeutics , Ltd (6892.TWO) FAQ

The latest current assets for 6892.TWO is $470M as of June 2026. That compares with $620M in the prior-year period — down 25.0% year over year. Investors often review this figure alongside Taiwan Bio Therapeutics , Ltd's historical trend and sector peers before judging valuation or financial health.

Over the past year, 6892.TWO's current assets moved from $620M to $470M — a 25.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Taiwan Bio Therapeutics , Ltd's operating scale or balance-sheet position.

A current assets figure of $470M for 6892.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 6892.TWO's current assets ($470M), review year-over-year change from $620M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Taiwan Bio Therapeutics , Ltd's current assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.